The 4 linked references in paper N. Uvarova E., N. Eremenko N., G. Ramenskaya V., D. Goryachev V., Н. Уварова Е., Н. Еременко Н., Г. Раменская В., Д. Горячев В. (2018) “ПЛАНИРОВАНИЕ И ОЦЕНКА ИССЛЕДОВАНИЙ БИОЭКВИВАЛЕНТНОСТИ ПРЕПАРАТОВ АТАЗАНАВИРА // PLANNING AND EVALUATION OF BIOEQUIVALENCE STUDIES OF ATAZANAVIR PRODUCTS” / spz:neicon:vedomostincesmp:y:2018:i:3:p:151-157

  1. Shimpi S. Bioequivalence study recommendation for atazanavir sulfate capsules by US FDA and a contrary view. Open Access Scientific Reports. 2012;1(8):388. https://doi.org/10.4172/scientific reports.388
  2. Sevinsky H, Tao X, Wang R, Ravindran P, Sims K, Xu X, et al. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents. Antivir Ther. 2015;20(5):493–500. https:// doi.org/10.3851/IMP2913
  3. Ромодановский ДП, Еременкова ТВ, Драницына МА, Горячев ДВ, Ниязов РР, Гавришина ЕВ, Меркулов ВА. Высоковариабельные лекарственные препараты — особенности исследования биоэквивалентности. Ведомости Научного центра экспертизы средств медицинского применения. 2015;(4):5–10. [Romodanovsky DP, Eremenkova TV, Dranitsyna MA, Goryachev DV, Niyazov RR, Gavrishina EV, Merkulov VA. Highly variable medicines — specific aspects of bioequivalence studies. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2015;(4):5–10 (in Russ.)]
  4. Haidar SH, Davit B, Chen ML, Conner D, Lee L, Li QH, et al. Bioequivalence approaches for highly variable drugs and drug products. Pharm Res. 2008;25(1):237–41. https://doi.org/10.1007/s11095007-9434-x ОБ АВТОРАХ